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In recent years, microbiota-associated neurodegenerative diseases have been
exploited and provided new insight into disease pathogenesis. However, primary
open-angle glaucoma (POAG), known as a complex neurodegenerative disease
resulting from retinal ganglion cell death and optic nerve damage, can cause
irreversible blindness and visual field loss. POAG, which shares several similarities
with Parkinson’s disease (PD) and Alzheimer’s disease (AD), has limited studies and
slow progression in the understanding of pathogenesis when compared to PD and AD.
In this review, we summarized the current knowledge of POAG and commensal
microbiota, combined with several lines of evidence in PD and AD to propose a
possible hypothesis for POAG pathogenesis: microorganisms cause glaucoma via
gut–retina axis, resulting in autoantibodies and autoreactive T cells that lead to
autoimmunity. Furthermore, dual-hit hypothesis, an example of a commensal
pathogen that causes PD, was partially exported in POAG. Finally, future perspectives
are suggested to expand understanding of POAG.
Keywords: primary open-angle glaucoma, microbiota, gut–retina axis,
pathogenesis, autoimmunity, neurodegenerative diseases
Introduction
Primary open-angle glaucoma (POAG) is recognized as an ocular
neurodegenerative disease via retinal ganglion cells (RGCs) death and causes
irreversible blindness as well as vision defects globally, leading to decreased
quality of life [1]. Glaucoma will affect approximately 79.6 million people by
2020 and increase to 111 million by 2040 [2, 3]. The disease is classified into
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elevated intraocular pressure (IOP) resulting from abnormal aqueous humor
flowing via the development of trabecular meshwork cell fibrosis [4] and normal
tension glaucoma (NTG; IOP< 22 mmHg). The end results of both types are
RGCs death via innate and adaptive immunity. In the elevated IOP type, current
treatments are IOP reduction composed of surgical intervention or medication.
Surgeries may be associated with potential vision-threatening consequences, while
the failure rate is approximately 11% [5–7]. For this reason, medication therapies
are considered the primary care option, which is a significant step in minimizing
the disease progression in the early stages of glaucomatous eye development.
However, currently available pharmacological treatments may cause adverse
effects and drug interactions. Long-term treatment can cause subclinical inflam-
mation and conjunctiva fibrosis development leading to increasing failure rates of
trabeculectomy [8–11]. The long-term treatment initially requires two or more
antiglaucoma drugs, which may predict failure in the present medication [5, 6].
Importantly, combination drug treatments are widely used for lowering IOP,
leading to low patient compliance with multiple daily administrations of eye
drops. Consequently, understanding of cellular and molecular pathogenesis is an
essential pathway to the development of novel interventions and therapies to
overcome glaucoma.
Besides the elevated IOP, NTG patients are also treated with IOP-lowering
medication. However, 12% of patients’ treatments are not successful in terms of
disease control. Moreover, the “Collaborative Normal-Tension Glaucoma Study”
showed that 30% of IOP reduction was not able to suppress visual loss.
These studies indicated that IOP management is not a prominent target for medica-
tion [12]. At present, Trivli et al. [13] suggest that this type of glaucoma is closely
associated with multifactorial components. The observational epidemiological study
shows that the ocular morphology of NTG is associated with visual field
defects, suggesting that ocular morphology dysregulation alters the
mechanical stress and axonal damage to destroy optic nerve heads and RGCs.
However, these findings remain controversial [13, 14]. In addition, vascular disorders
composed of vascular dysregulation, neovasculization, and ischemia have been
proposed as a pathogenesis of NTG [15]. Gherghel et al. [16] showed that ocular
blood flow of a patient, as measured using the mean of a peripheral laser Doppler,
was altered depending on the temperature. A cold provocation test illustrates that the
instability of both mean ocular perfusion pressure and blood pressure (BP) occurred
in patients compared to healthy controls [17]. In a prospective clinical validation
study, the NTG patients impaired autonomic cardiovascular regulation, analyzed by
an alteration in BP variability and heart rate during resting conditions [18]. In a rabbit
experimental model, the instability, induced endothelin-1 injection of the optic nerve,
and blood flow resulted in RGC loss [19]. The current model suggests that it is the
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effect of chronic oxidative stress, known as ischemia-reperfusion injury [20].
However, these models do not offer a complete understanding of POAG pathogene-
sis as there are several factors associated with POAG, such as genetic predisposition
and iron-deficiency anemia [21, 22]. An initiation of POAG is still ambiguous and
pathogenesis has not been clearly elucidated.
Previously, the pathophysiological features of glaucoma were compared
with other neurodegenerative diseases, especially Parkinson’s diseases (PD) and
Alzheimer’s disease (AD), leading to the reclassification of glaucoma as optic
neuropathy with effects in the central nervous system (CNS). The optic nerve is a
part of the CNS. Several similarities in clinical manifestations, such as age,
presymptomatic stage, clinical progression, genetic predisposition, and cellular
pathogenesis, have been found to be shared between glaucoma and neurodegen-
erative diseases [23, 24]. For this reason, the study of PD and AD may provide
new insight into glaucoma disease.
In the past decade, human microbiota has been rapidly exploited into
neurodegenerative diseases and autoimmunity. The alteration of intestinal
microbiome into pathogenic bacteria or other groups of bacteria has been broadly
recognized as microbial dysbiosis and plays a role as a contributing factor in disease
pathogenesis [25, 26]. Intestinal gut microbiota is well characterized as a
confounding factor in several diseases such as amyotrophic lateral sclerosis (ALS),
multiple sclerosis (MS), AD, and PD, since the gut microbiome is facile and
changed via diet and exercise [27–30]. A microbiota–gut–brain axis is a cross-talk
between gut and microbiota, in which enteric bacteria are able to enter the
circulation and pass the blood–brain barrier (BBB), known as the humoral pathway,
to penetrate the CNS via the vagus nerve, which is a neural pathway [31, 32]. In
addition, a dual-hit hypothesis was applied in PD, where a pathogen invades the
brain through an immunoprivileged site like the eye of the host by gut and nose [33].
A population-based follow-up study covering 8 years showed that POAG was
significantly associated with AD and saved as an AD predictor [34], suggesting that
there is a potential link between brain degenerative diseases and glaucoma and
retinal degenerative disease. Therefore, this review will summarize and propose the
microbiota–gut–retina axis and dual-hit hypothesis as potential pathogenesis in
POAG based on current knowledge of brain neurodegenerative diseases and
glaucoma studies, which may be applied for the development of a novel therapy.
Commensal Microbiota: From Neurodegenerative Diseases to POAG
Microbial dysbiosis is a crucial player in the onset of neurological disorders
and progressive neuronal loss, including ischemic reperfusion injury [25, 35].
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In a mouse model, the gut microbiota was strongly associated with AD. For
example, intensity-dependent chronic noise exposure reduced gut microbiota
diversity and caused the increase of inflammatory mediators, resulting in
AD-like effects in the brain [36]. Significant differences in abundance of gut
microbiota were shown when comparing between senescence-accelerated mouse
prone 8 (SAMP8), recognized as well established deterministic of AD, and
senescence-accelerated mouse resistance 1; as such, Lachnospiraceae, Alistipes
species, Akkermansia species, and Odoribactor species were enriched in SAMP8
[37]. To confirm this relationship, the Drosophila model with AD pathology
showed various groups of commensal bacteria [38]. Recent human study revealed
that the bacterial diversity of gut microbiota in AD patients is distinctive from
normal controls, such as Actinobacteria, Bacteroides species, Ruminococcus
species, Selenomonadales, and Lachnospiraceae [39]. Therefore, these are able
to imply that the perturbation of commensal microbiota is involved in the
pathogenesis of AD. Xu and Wang [40] suggested that the gut microbial
metabolites should be considered as biomarkers because there is a positive
correlation with disease progression in AD.
Regarding AD, several studies of the PD model also found a correlation
between gut microbiota and disease pathogenesis, in which dopaminergic neurons
were devastated by the aggregation and accumulation of α-synuclein (αSyn)
[26, 41]. In dual-hit hypothesis (Braak’s hypothesis), the antigens may enter via
the nasal and gastric pathways. The enteric nervous system is the early site of
αSyn, which subsequently locates in the brain via the vagus nerve [33, 42]. In the
clinical study, the decreasing of Lachnospiraceae and increasing of Lactobacil-
laceae as well as Christensenellaceae are associated with the severity of idiopathic
PD [43]. Furthermore, PD patients were commonly found to have extraordinary
increases in coliform bacteria in intestinal microbiome overgrowth [44, 45].
Importantly, there is bias in anti-inflammatory bacteria and pro-inflammatory
bacterial microbiome between PD patients and healthy controls. Butyrate-
producing bacteria, normally genera Blautia, Coprococcus, and Roseburia, were
reduced in the feces of PD. On the contrary, Ralstonia genus, pro-inflammatory
bacteria, was predominant in healthy controls compared to PD patients [46]. As a
result, the balancing of inflammatory response might regulate gut microbiota,
which is associated with PD pathogenesis. A colonic biopsy sample of PD
patients, in which dysbiosis was detected by the decreasing of short-chain fatty
acids compared to healthy controls, increases Toll-like receptor 4 (TLR4),
cytokine expression, and CD3+ T cells. Moreover, TLR4 knockout mouse,
induced using oral rotenone, indicated that lower intestinal and motor dysfunction
including neurodegenerative and neuroinflammation suggested that innate
immunity may play a role in microbial dysbiosis in PD [47].
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Gastrointestinal permeability saves as an anatomic barrier and one explana-
tion of microbiota and brain damage [25]. Increased permeability is able to
disseminate bacterial components or pathogens to the blood and brain [48, 49]. By
way of illustration, the level of lipopolysaccharides (LPS) in serum roughly
increases in AD and sporadic ALS patients. It is capable of activating monocytes
and decreasing IL-10 [50]. In a rat model, the disruption of gut-barrier function
and dysbiosis results in bacterial translocation [51]. Importantly, the BBB integrity
of AD is decreased, which leads to immune activation [52]. Another example is a
cohort observation in PD patients, where the αSyn, and serum LPS-binding
protein, endotoxin marker were increased and associated with intestinal hyper-
permeability [53]. Among these studies, it was suggested that gastrointestinal
permeability has a connection to the dissemination of antigens or inflammatory
factors to the brain.
At present, several diets have the ability to increase epithelial permeability
[54] and alter microbiota. As a case in point, unsaturated fatty acid diets affect
microbial varieties and increase eightfold in intestinal permeability in a mouse
model [55] as well as chicken feeding with different patterns, ad libitum versus
restrictive feeding, represented cecal microbiota deviation and may potentially
disturb intestinal physiology including morphology and permeability [56].
Furthermore, there is evidence to support that commensal bacteria microorganisms
interface with permeability. Chen et al. [57] elucidated that microbial treatment,
Lactobacillus rhamnosus GG, improves intestinal permeability and modulates
dysbiosis results in a protective role in a sepsis mouse model. Other treatment
examples are Puerariae Lobatae Radix and Chuanxiong Rhizoma, which showed
that this combination is able to rebalance gut microbiota dysbiosis and revive
gut–brain barrier disruption [58].
The roles of commensal microbiota in ocular disease are slowly being
explored, but are significantly important [59]. Previously, Horai et al. performed
spontaneous uveitis on a mouse model and showed that commensal bacteria activate
T cells by non-cognate interaction and subsequently promote autoreactive T cells
infiltration across blood–retinal barriers. The autoreactive T cells respond to
autoantigen in the retina and result in inflammation [60]. In experimental
autoimmune uveitis, the pathology was induced by interphotoreceptor-binding
peptides, indicating the alteration of gut microbiome via oral antibiotics adminis-
tration associated with uveitis severity [61]. A recent study in animal models
coupled with adoptive transfer experiments that activated immune response by
antigen injection through the anterior chamber, which should activate T cells in the
spleen or thymus via anterior chamber-associated immune deviation (ACAID),
showed retinal neurodegeneration resulting from heat shock proteins (HSPs)-
specific CD4+ Th1, which requires priming from commensal bacteria [62, 63].
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Altogether, dysbiosis is also involved in basic glaucoma pathogenesis, similar to
other neurodegenerative diseases. Therefore, the microbiota–gut–retinal axis is
possible.
A common example of commensal pathogenic bacteria is Helicobacter
pylori, which was reclassified as extragastroduodenal diseases such as immune
thrombocytopenic purpura and iron-deficiency anemia [64]. Accordingly,
H. pylori cause other diseases. Many studies have supported that infected patients
significantly increase the risk of developing several neurodegenerative diseases
including PD, AD, MS, and POAG [65–68]. In meta-analysis and case–control
study, PD patients infected with H. pylori showed higher severity of PD and
H. pylori eradication therapy to improve disease severity, suggesting that com-
mensal pathogens may contribute to disease deterioration [66]. This is in accor-
dance with glaucoma studies. Kountouras et al. [69] showed that H. pylori
eradication decreases IOP and improves visual field. In a study by Atilgan
et al. [70], the H. pylori infection decreased temporal quadrant retinal nerve fiber
layer thickness when compared between pretreatment and posttreatment to
eradicate H. pylori infection from patients, indicating the early signs of glaucoma.
Surprisingly, H. pylori can be detected in trabeculectomy specimens of patients,
suggesting that bacteria can successfully colonize trabecular meshwork cells [71].
This evidence shows that the microbiota–gut–retina axis is available in our body,
although the translocation route remains unknown.
In addition, the specific H. pylori IgG antibody is able to be found in the
serum and aqueous humor of POAG patients [72, 73]. Increasing the IgG
antibody is possible for cross-reactivity with ocular tissue [74]. Previous
researches showed that H. pylori activate autoantibodies via molecular mimicry
in autoimmune disorders such as cardiovascular and autoimmune thyroid
disease [75, 76]. H. pylori-seropositive PD patients upregulated eight
autoantibodies when compared with H. pylori-seronegative PD patients [77].
In glaucomatous tissue, HSPs are increased and play a role in neurodegenera-
tion [78, 79], which is a potential target of autoantibodies due to the high level
of sequence homology with microbial HSPs [80]. In human studies, HSPs-
specific autoantibodies and other autoantibodies increase in the serum and
aqueous humor of glaucoma patients [81–83]. Ex vivo stimulation by HSP60 in
glaucoma peripheral blood monocyte showed Th2 bias [84]. This study in blood
samples of glaucomatous patients compared with non-glaucomatous controls
exhibited a trend toward decreased frequency of regulatory T cell. Ex vivo
stimulation by a specific antibody to ε chain of human CD3, CD28, and CD137
revealed CD4+ T response in glaucomatous samples [85]. In an animal model, a
glaucomatous formation and RGCs loss were induced by HSPs [86, 87].
Adoptive transfer of T and B cells from glaucomatous mice provokes
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detrimental outcome in normal recipient mice [88]. For this reason, it might
suggest that T-helper cell and B cell can circulate to the eye and destroy the
retina cells resulting in the progression of visual field loss.
Finally, the other innate immunity may collaborate to augment the
pathology of glaucoma. For example, pathogen-associated molecular pattern
recognitions are involved in glaucoma pathogenesis. For instance, the TLR4
may be the critical player in recognizing HSPs as damage-associated molecular
patterns in glaucoma [89]. This is consistent with H. pylori, producing
miscellaneous antigens that activate the immune system by TLRs and increase
TLR4 expression in gastric epithelial cells [90, 91]. Taken together, a commen-
sal bacterium such as H. pylori may be one actor in glaucoma pathogenesis by
causing autoimmunity.
In summary, we proposed a hypothesis for glaucoma, neurodegenerative
disease, and autoimmunity resulting from orchestrations of T and B cells, in
which bacteria or endotoxins are able to migrate to the ocular region using the
microbiota–gut–retina axis via alteration of gastrointestinal permeability and
increased inflammatory cytokines and autoantibodies in the blood and aqueous
humor. H. pylori are able to enter the eye through unknown routes of transloca-
tion. Commensal bacteria can shed antigens to blood and is subsequently
captured in the spleen, an important organ of ocular immunity, which causes
ACAID, resulting in immune cell activation as well as homing to the ocular
region. Furthermore, the antigens may appear in the anterior chamber resulting in
Th1 development, which requires the commensal gut microbiota. Therefore,
dysbiosis may initiate the step of POAG development by priming immunity
(Figure 1).
Oral Microbiota: A Possible Source of Antigens That May Cause Glaucoma
Other examples of microbiota in neurodegenerative diseases are oral
microbiota dysbiosis. Oral pathogens such as Porphyromonas gingivalis and
Treponema forsythia are associated with AD and able to be found in the brain of
AD patients [92–94]. Recently, the reduction of P. gingivalis toxin, gingipains,
was able to decrease the bacterial load in the brain and abate neuroinflammation
[95]. However, no direct evidence has shown that oral pathogens are associated
with glaucoma. In this field, Astafur et al. carried out the first study that showed
oral bacteria load significantly increases in mouthwash specimens from glaucoma
patients using 16s RNA and pyrosequencing. However, there are confounding
factors appearing in this study. The results showed significant differences in age,
gender, and diabetes status [96]. Consequently, the data were stratified and showed
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Streptococcus spp. in glaucoma cases when compared with control [97]. Recently,
dental health identified by the number of natural teeth was proposed as a marker
for glaucoma. However, there are some controversies that should be addressed and
validated in a large sample group. Moreover, classified periodontal status with
other factors may affect the study [98, 99].
Figure 1. The possible model of glaucoma pathogenesis is autoimmunity disease. The gut
microbiota is able to shed the antigens or translocate the bacterium to the outside of the
gastrointestinal tract via the alteration of epithelial permeability. The antigens may activate Th2
development and increase antibodies by unknown mechanisms. Moreover, the routes of bacteria
migration are undercharacterized. The trabecular meshwork (TM) cells are able to recognize both
autoantigens, the bacteria antigens, and damage-associated molecular pattern (DAMPs) using
pathogen-associated molecular pattern (PAMPs), such as TLR4, and autoantibodies to generate
imbalanced signaling of inflammation, which causes retinal damage as a consequence. In addition,
the activation of autoreactive T cells by antigen induction in anterior chamber results in anterior
chamber-associated immune deviation (ACAID). This mechanism is not fully understood, although
it requires the commensal microbiota, resulting in Th1 development and inflammation in the eye.
This should be further investigated in the future
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Nutrition Behavior May be Considered as Supplement for Glaucoma Patients
As previously mentioned, gastrointestinal permeability is altered depend-
ing on diet and microbiota. Supplementation of high fat and protein diets was an
increase of bacteria in the gut such as Alistipes, Bacteroides, and Bilophila
organisms, whereas the diet enriched with a high sugar caused a decrease of the
beneficial gut microbiome (Lactobacillus, Ruminococcaceae, and Lachnospir-
aceaeae) [100–102]. These may directly or indirectly affect the cause of
glaucoma. Several lines of evidence suggested that omega fatty acids, caffeine,
and ketogenic diet have been reported to provide a neuroprotective role in
glaucoma [103, 104]. In the clinical study, carbohydrate ingestion in POAG
patients showed systemic autonomic dysregulation [105]. Ketogenic diets,
modified gut microbiota, and permeability may play a role in the neuroprotection
of glaucoma [106–108]. A population-based study in Japan suggested the
consumption of meat, which is positively associated with open-angle glaucoma
[109]. In Canada, a multicenter cross-sectional study reported that approximately
one in nine glaucoma patients apply complementary and alternative medicine,
including diets, for their disease [110]. Accumulation of studies showed that
these diets convert gut microbiome [107].
Nowadays, the current research suggested that an individual’s diet might
have an impact on IOP and progression of the disease [111]. It may help people to
improve and maintain their eyesight. A study found that salt-enriched diet intake is
associated with a decreasing IOP in the eyes [112]. Thus, proper salt consumption
may be the benefit for glaucoma patients. In addition, it is also found that
combination of retinol and vitamin B1 seems to involve in glaucoma progression
especially in the high dose [113]. Moreover, high-antioxidant foods, including
leafy green vegetables, flavonoid-rich fruits, and red wine, propose a low risk of
glaucoma [114–116]. In this regard, we speculated that there is some relation
between diets, commensal microbiota, and immunity in the eye, which may cause
inflammation and retina damage, resulting in glaucoma. Therefore, we suggested
that to improve the effectiveness of lowering IOP medication, nutrition manage-
ment should not be neglected.
Further Perspective
POAG is a disease that significantly affects the quality of life. Current
medication therapies are able to slow disease progressions but may be associ-
ated with drug resistance during prolonged treatment. Therefore, understanding
of glaucoma pathogenesis is a significantly pivotal approach. At present, innate
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lymphoid cells play a key role in autoimmunity, although glaucoma has a gap in
this area. Moreover, the microbiome has rapidly progressed. The gut–retina
axis is possible, as mentioned earlier. The route of migration should be
identified in the future. How the gut–microbiota activates T and B cells to
produce the autoantigens, which are able to react with ocular antigens? How
many cell types are associated with this mechanism? In addition, how the
ACAID involved in glaucoma and autoimmunity should be linked with gut
microbiota? These uninvestigated questions were shown in Figure 1. Finally,
oral microbiota is also important due to the association between oral infection
and neurodegenerative diseases. To answer this question, a cohort study of
periodontal disease and commensal infection should not be neglected
in glaucoma study. Finally, diet may be adopted as a contributing factor for
glaucoma pathogenesis and may be applied in combinatorial treatment for
glaucoma patients. These aspects should be confirmed in a laboratory with
epidemiological effort.
Conclusions
POAG concepts have been modified in the past decade. Advances in
science and technology have been exploring and explaining glaucoma patho-
genesis from several aspects, especially autoimmunity. Our review summa-
rized the relationship between glaucoma and commensal bacteria, which
resulted in one possible hypothesis: microorganisms prime the immune cells
to breakdown self-tolerance and cause autoimmunity. The commensal dys-
biosis locates to the eye by gut–retina axis, although the route of translocation
is underinvestigated. For this reason, a sufficient-component cause model
should be revised or reconsidered. Finally, we suggested a potential way to
slow the progression of the disease using diet coupled with medication
treatment. However, the pathogenesis has multidisciplinary factors that affect
and cause the disease.
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